Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ascenta Therapeutics and sanofi-aventis have entered into a collaboration and licensing agreement covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death).
Subscribe to our email newsletter
Ascenta Therapeutics and sanofi-aventis said that these orally-active, small-molecule drug candidates remove a block to normal p53 tumor suppressor function and inhibit the interaction between HDM2 (Human Double Minute 2) and p53, thus enhancing cancer control and treatment.
As per the terms of the agreement, sanofi-aventis has received from Ascenta Therapeutics an exclusive worldwide license to develop, manufacture and commercialise all compounds issued from this program.
Under the agreement, Ascenta is expected to receive an upfront payment, as well as development, regulatory and commercial milestone payments that could reach a total of $398m. In addition, Ascenta is eligible to receive tiered royalties on worldwide product sales.
Ascenta Therapeutics and sanofi-aventis stated that the agreement includes two agents that Ascenta Therapeutics previously in-licensed from the University of Michigan, MI-773 and MI-519-64.
Both the companies are expected to continue to fund research on these targets at the University of Michigan, and Ascenta Therapeutics may participate in ongoing research activities and potential future clinical development.
Mel Sorensen, president and CEO of Ascenta Therapeutics, said: “Restoring tumor suppressor function through the inhibition of the HDM2-p53 interaction is expected to control and prevent cancer progression.”